What's Happening?
At the Asembia 2026 summit, EVERSANA's Krista Pinto discussed key trends in the pharmaceutical industry, focusing on the increasing demand for AI, outsourcing, and strategic partnerships. Pinto noted that patient access, affordability, and speed-to-therapy
are top challenges, with companies seeking efficient operations amidst pricing pressures and regulatory changes. The summit highlighted a shift towards integrated partnerships for commercialisation services, as companies look for comprehensive support to manage complex market dynamics. AI was a central topic, with clients interested in practical applications that deliver measurable outcomes, particularly in forecasting and operational efficiency.
Why It's Important?
The insights from Asembia 2026 reflect broader industry trends where pharmaceutical companies are increasingly relying on AI and outsourcing to navigate a complex and fast-paced market. This shift is significant as it indicates a move towards more strategic and integrated approaches to commercialisation, which can enhance efficiency and effectiveness in bringing new therapies to market. The focus on AI integration suggests a growing recognition of its potential to transform operations and improve patient outcomes, making it a critical component of future pharmaceutical strategies.
What's Next?
As the demand for outsourced services and AI solutions continues to rise, pharmaceutical companies are likely to form more long-term partnerships with service providers like EVERSANA. These partnerships will focus on integrating AI into core operations to enhance efficiency and effectiveness. The industry may also see increased investment in AI technologies and infrastructure to support these initiatives. Companies that successfully leverage these trends could gain a competitive advantage in the market by improving access to therapies and optimizing their commercialisation strategies.
